Drug Name:
EXELON Rx
Generic Name and Formulations:
Rivastigmine (as tartrate) 1.5mg, 3mg, 4.5mg, 6mg; caps.
Company:
Novartis Pharmaceuticals Corp
Therapeutic Use:
Indications for EXELON:
Mild-to-moderate dementia of the Alzheimer's type.
Adult:
Take with food in the AM and PM. Initially 1.5mg twice daily; if well-tolerated, may increase by 1.5mg twice daily at intervals of at least 2 weeks. Usual range: 6–12mg/day; max 12mg/day. If dose is not tolerated, suspend for several doses and restart at same or next lower dose. If stopped for >3 days, restart at 1.5mg twice daily and retitrate. Moderate-to-severe renal or mild-to-moderate hepatic impairment: use lower doses. Low body wt. (<50kg): monitor for toxicities and consider reducing dose.
Children:
<18yrs: not recommended.
Contraindications:
Patches: previous history of application site reactions suggestive of allergic contact dermatitis (in the absence of negative allergy testing).
Warnings/Precautions:
Monitor for nausea, vomiting, anorexia, weight loss, GI bleed. Sick sinus syndrome, other supraventricular conduction disturbances. Seizures. History or risk of ulcers. Urinary obstruction. Asthma. COPD. Discontinue if disseminated allergic dermatitis occurs. Renal or hepatic impairment. Pregnancy. Nursing mothers.
See Also:
Pharmacological Class:
Reversible acetylcholinesterase inhibitor (carbamate deriv).
Interactions:
Concomitant metoclopramide, beta-blockers, cholinomimetics, anticholinergics: not recommended. May potentiate succinylcholine-type muscle relaxants. Monitor for GI bleed with NSAIDs.
Adverse Reactions:
Nausea, vomiting, anorexia, dyspepsia, asthenia, diarrhea, abdominal pain, dizziness, weight loss, tremor, cholinergic effects; also, patches: application site reactions, allergic contact dermatitis (discontinue if suspected or no improvements within 48hrs after removal; or consider switching to oral form only after negative allergy testing; monitor).
Generic Availability:
YES
How Supplied:
Caps—60, 500; Patches—30
Indications for EXELON:
Mild-to-moderate dementia associated with Parkinson's disease.
Adult:
Take with food in the AM and PM. Initially 1.5mg twice daily; if tolerated, may increase by 1.5mg twice daily at intervals of at least 4 weeks. Usual range: 3–12mg/day; max 12mg/day. If dose is not tolerated, suspend for several doses and restart at same or next lower dose. If stopped for >3 days restart at 1.5mg twice daily and retitrate. Moderate-to-severe renal or mild-to-moderate hepatic impairment: use lower doses. Low body wt. (<50kg): monitor for toxicities and consider reducing dose. Patch: Apply to clean, dry, hairless intact skin. Rotate application site (allow 14 days before reapplying to same site). Initially apply one 4.6mg/24hrs patch once daily; if tolerated, may increase to 9.5mg/24hrs patch after 4 weeks at previous dose; can further be increased to max 13.3mg/24hrs dose. If dosing interrupted for >3 days, restart with 4.6mg/24hrs patch and retitrate. Mild-to-moderate hepatic impairment: initial and max dose 4.6mg/24hrs patch. Low body wt. (<50kg): monitor for toxicities and consider reducing maintenance dose to 4.6mg/24hrs patch. Switching from capsules: see full labeling.
Children:
<18yrs: not recommended.
Contraindications:
Patches: previous history of application site reactions suggestive of allergic contact dermatitis (in the absence of negative allergy testing).
Warnings/Precautions:
Monitor for nausea, vomiting, anorexia, weight loss, GI bleed. Sick sinus syndrome, other supraventricular conduction disturbances. Seizures. History or risk of ulcers. Urinary obstruction. Asthma. COPD. Discontinue if disseminated allergic dermatitis occurs. Renal or hepatic impairment. Pregnancy. Nursing mothers.
See Also:
Pharmacological Class:
Reversible acetylcholinesterase inhibitor (carbamate deriv).
Interactions:
Concomitant metoclopramide, beta-blockers, cholinomimetics, anticholinergics: not recommended. May potentiate succinylcholine-type muscle relaxants. Monitor for GI bleed with NSAIDs.
Adverse Reactions:
Nausea, vomiting, anorexia, dyspepsia, asthenia, diarrhea, abdominal pain, dizziness, weight loss, tremor, cholinergic effects; also, patches: application site reactions, allergic contact dermatitis (discontinue if suspected or no improvements within 48hrs after removal; or consider switching to oral form only after negative allergy testing; monitor).
Generic Availability:
YES
How Supplied:
Caps—60, 500; Patches—30
Clinical Pain Advisor Articles
- MRS May Accurately Identify Painful Disks in Chronic Low Back Pain
- Examining the Relationships Among Opioid Use, Overdose, and Suicide
- Multispecies Probiotics May Be Effective in Chronic, Episodic Migraine
- Migraine Symptoms Can Improve Despite Unchanged Pain Avoidance, Endurance
- Mindfulness-Based Stress Reduction Also Benefits Chronic Pain
- MRS May Accurately Identify Painful Disks in Chronic Low Back Pain
- Does Opioid Tapering in Chronic Pain Result in Controlled Pain at Taper Completion?
- Spinal Cord Stimulation Shows Long-Term Effectiveness for Refractory Neuropathic Pain
- Color Doppler Ultrasound for the Diagnosis of Sacroiliitis in Inflammatory Back Pain
- An Evidence-Based Road Map to Navigating the Opioid Epidemic
- Headache Frequency, Medication Overuse, and Depression Linked to Migraine
- Giving the Choice of Medical Support During Painful Procedures to Children With Cancer
- Mechanisms of Posttraumatic Headache
- Parents Conflicted About Opioid Use in Children
- Generalized Mechanical Hyperalgesia in Chronic Migraine, Temporomandibular Disorder